SCHEMBL5544065

SCHEMBL5544065

[CH2]CCCCCc1ccc(C(N)=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 1/20 0.47
PLA2G2A P14555 1/20 0.47
THRA P10827 9/20 0.46
THRB P10828 9/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HDAC1 Q13547 1/20 0.45
PARP10 Q53GL7 1/20 0.44
RARB P10826 4/20 0.44
ALDH1A1 P00352 1/20 0.44
RARA P10276 1/20 0.44
MAPT P10636 1/20 0.44
MTOR P42345 1/20 0.44
FAAH O00519 1/20 0.41
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3067418 0.98 PLA2G10 (0.48) PLA2G10PLA2G2ATHRATHRBMEN1
SCHEMBL5330371 0.92 PLA2G10 (0.50) PLA2G10PLA2G2ATHRATHRBMEN1
SCHEMBL5536952 0.84 PLA2G10 (0.53) PLA2G10PLA2G2AKMT2APARP10ALDH1A1
SCHEMBL5020708 0.83 PLA2G10 (0.69) PLA2G10PLA2G2AHDAC1PARP10MAPT
SCHEMBL9100795 0.83 RARB (0.62) THRATHRBMEN1KMT2AHDAC1
SCHEMBL13617729 0.81 THRA (0.65) THRATHRBMEN1KMT2ARARB
SCHEMBL75644 0.81 THRA (0.65) THRATHRBMEN1KMT2ARARB
SCHEMBL351935 0.81 THRA (0.65) THRATHRBMEN1KMT2ARARB
SCHEMBL6835676 0.81 THRA (0.65) THRATHRBMEN1KMT2ARARB
SCHEMBL4931942 0.81 THRA (0.65) THRATHRBMEN1KMT2ARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PLA2G10 4881/4885PLA2G2A 4685/4885THRA 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.